drugset / Trial / NCT02249403
Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this trial was to assess the dose-response relationship of symptomatic efficacy of talsaclidine base on ADAScog and to assess safety and tolerability
Timeline
- Start
- 1999-01
- Primary completion
- 2000-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talsaclidine | Small molecule | 6 mg | Oral |
| Subject | Talsaclidine | Small molecule | 12 mg | Oral |
| Subject | Talsaclidine | Small molecule | 24 mg | Oral |
| Subject | Talsaclidine | Small molecule | 36 mg | Oral |